BUSINESS WIRE – Allurion Technologies, a pioneering leader in the development of innovative, scalable and trusted weight loss experiences, today announced results from three key abstracts presented at the 24th World IFSO Congress. The abstracts examine the Elipse Program — featuring the Elipse Balloon, the world’s first and only procedureless medical device for weight loss — and show significant decreases in both weight and cardiovascular disease markers, such as LDL cholesterol and hemoglobin A1c, in patients who have used the balloon for weight loss.